Therefore, both IL-6 and TNFR2 may contribute to the tumour-promoting roles of STAT3, hence targeting the IL-6-signaling pathway may help to decrease maximally suppressive TNFR2+ Tregs. Here, STAT3 is linked to neoplasm.